We open different perspectives to healthcare market players

Advising, projects & support for public and private health organizations Company profile - 2015

www.hittinnova.com

What’s the real meaning of ‘success’?

• 22 of these 23 people

have something in

common: they didn’t

set up a company.

Although no one

denies that they were

great scientists…

• Only one of them,

Ernst Solvay,

estabished a

succesful business.

Health Innovation Technology Transfer 1

Seated (L-R): Walther Nernst, Marcel Brillouin, Ernest Solvay, Hendrik Lorentz, Emil Warburg, Jean Baptiste Perrin, Wilhelm Wien, Marie Curie, and Henri Poincaré. Standing (L-R): Robert Goldschmidt, Max Planck, Heinrich Rubens, Arnold Sommerfeld, Frederick Lindemann, Maurice de Broglie, Martin Knudsen, Friedrich Hasenöhrl, Georges Hostelet, Edouard Herzen, James Hopwood Jeans, Ernest Rutherford, Heike Kamerlingh Onnes, Albert Einstein, and Paul Langevin.

www.hittinnova.com

Failure in BioTech is a constant

• If failure means liquidating all assets, with

investors losing most or all the money they

put into the company, then the failure rate for

start-ups is 30 to 40 percent

• If failure refers to failing to see the projected

return on investment, then the failure rate is

70 to 80 percent

• If failure is defined as declaring a projection

and then falling short of meeting it, then the

failure rate is a whopping 90 to 95 percent

Health Innovation Technology Transfer 2

Illusions of Entrepreneurship: The Costly Myths that Entrepreneurs, Investors, and Policy Makers Live Scott Shane , Professor of Entrepreneurial Studies at Case Western Reserve University

New business founded in 1992 still alive by year

www.hittinnova.com

Successful ways always jump outside the box

• Nowadays, independent and honest visions

are critical factors for success in the

innovation & technological projects of health

players.

• Through a different and unconventional

view, hitt generates relevant and timely

information for both public entities and

private companies, to inform their

investment and strategic development

decisions.

• Excellence, accountability and team efficiency

are our key performance advantages.

Health Innovation Technology Transfer 3

Technology life-cycle

www.hittinnova.com

Services

Health Innovation Technology Transfer 4

ADVISING Trusted independent advisors for public and private health

organizations

PROJECTS Experts consultants on

business, investment and clinical development strategies

SUPPORT High quality and broad reviews

of best state-of-the-art in health market

We deploy a full range of solutions to cover the main needs of knowledge of all

actors in health market.

www.hittinnova.com

The three pillars of development

Health Innovation Technology Transfer 5

Science Organization

Finance

Start-ups often fail because founders and investors neglect to

look before they leap, surging forward with plans without taking the time to realize that the base

assumption of the business plan is wrong. They believe they can

predict the future, rather than try to create a future with their

customers. Entrepreneurs tend to be single-minded with their

strategies—wanting the venture to be all about the technology or all about the sales, without taking

time to form a balanced plan. And all too often, they do not give themselves wiggle room to pivot

midstream if the initial idea doesn't jibe with customer

demand. Shikhar Ghosh, Senior Lecturer of Business Administration, Harvard

Business School

Registry Price Financing

Regulatory Health Authorities

FDA: security & efficacy

EMA: quality, safety & efficacy

CMS: Reasonable & Necessary

CatSalut: appropriate adjustment of supply to the health

needs of citizens NHS UK:

comprehensive range of services

Insurer

www.hittinnova.com

The current strategy…

Health Innovation Technology Transfer 6

Idea PoC Regulatory Clinical Development

Marketing / KOL

Commercial

Basic Science / Experts

Operations

www.hittinnova.com

… and the hitt approach

Health Innovation Technology Transfer 7

Marketing / KOL

Commercial

Basic Science / Experts

Operations

Primary

Research

Early

Stage

Market

Access Market

System Overview / Designing access strategies

www.hittinnova.com

Focus on

We design easier and more profitable ways for:

• To build and consolidate strategic decisions in market access for health products & services

• To support start-ups on their business strategy &development

• To generate primary research in health services

Health Innovation Technology Transfer 8

Primary

Research

Early

Stage

Market

Access Market

www.hittinnova.com

Providing key data

• Review of literature

• Develop a business strategy & implement business ‘thinking’

• Landscape analysis & define relevant outcomes

• Feasibility studies (cost / operational / clinical)

• Cost-Effectiveness & Budget impact analysis (Economic

Evaluation)

• Impacts on the organizations & on clinical management

• Analyse alternatives / comparators

• Propose pricing scenarios

Health Innovation Technology Transfer 9

Primary

Research

www.hittinnova.com

Early

Stage

Opening new paths to success

• design and implement roadmap

• validate research proposals

• validate expected outcomes

• assess business value

• refine value proposition

• early stage investing strategy

• design and implement clinical trials

Health Innovation Technology Transfer 10

www.hittinnova.com

Market

Access

Designing business strategies

• Analyse & propose possible pricing scenarios & strategies

• Recommend (and elaborate) value dossier content, and

incorporate HTA perspective

• Probe intangible value

• Economic evaluation of research findings

• Validate expectations of Return on Investment: inform on potential

risks and mitigate and arise threats

• Development phase projects:

• Definition of most relevant outcomes

• Research & economic evaluation trials

• Facilitate appropriate development of PoC and Research Trials: Sites, KOL.

Health Innovation Technology Transfer 11

www.hittinnova.com

Projects

• hitt develops projects for top pharma companies, start-ups, government agencies

and consultancy firms in health industry.

• Some of our clients are:

Alcon · Novartis · Biomarin · BiogenIdec · ALKAbelló · Bayer · Shire ·

Astellas · Otsuka · Astra Zeneca · Hartmann · Reig Jofre · Oryzon Genomics ·

Oliver Wymann · Quintiles · Ernst&Young · Deloitte · Ernest&Young ·

Simon Kutcher & Partners · Antares Consulting · UBC ·

IMS · Ysios Capital · Proa Capital

Health Innovation Technology Transfer 12

www.hittinnova.com

How we work?

• Independent and small dynamic team, knowledgeable of both the EU and US

environments

• Alliances with the best-of-breed providers.

• Incorporating ad-hoc specialists to achieve best available expertise on a

timely and high quality manner

• Based on a network of free-standing senior international collaborators, who

have been or are in strategic decision positions mainly in the EU.

• Two stage approach

• We shall inform our clients in less than 2 weeks on the foreseen outcome of

the project, allowing them to reshape objectives

Health Innovation Technology Transfer 13

www.hittinnova.com

c/Avenir, 1

08006 Barcelona

T. +34 650 161 197

info@hittinnova.com

info@hittinnova.com